Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Sutent

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    At ASCO 2026, A 'Paradigm Shift' For A Rare Gut Cancer Looms
    At ASCO 2026, A 'Paradigm Shift' For A Rare Gut Cancer Looms

    01 Jun 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/asco-2026-paradigm-shift-rare-gut-cancer-looms

    FIERCE BIOTECH
    01 Jun 2026
    Share Share
    Cogent's Bezuclastinib Phase 3 PEAK Data in GIST at ASCO
    Cogent's Bezuclastinib Phase 3 PEAK Data in GIST at ASCO

    30 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/30/3303872/0/en/cogent-biosciences-announces-detailed-clinical-data-from-peak-phase-3-trial-with-bezuclastinib-in-combination-with-sunitinib-in-gastrointestinal-stromal-tumors-gist-at-2026-america.html

    GLOBENEWSWIRE
    30 May 2026
    Share Share
    Cogent Bio Announces NDA with Priority Review for Bezuclastinib
    Cogent Bio Announces NDA with Priority Review for Bezuclastinib

    28 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/28/3302753/0/en/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-nda-with-priority-review-for-bezuclastinib-in-combination-with-sunitinib-for-patients-with-gist.html

    GLOBENEWSWIRE
    28 May 2026
    Share Share
    Cogent’s Bezuclastinib Combo Gains FDA Breakthrough Status
    Cogent’s Bezuclastinib Combo Gains FDA Breakthrough Status

    26 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/26/3225587/0/en/Cogent-Biosciences-Announces-Breakthrough-Therapy-Designation-for-Bezuclastinib-in-Combination-with-Sunitinib-for-Patients-with-Gastrointestinal-Stromal-Tumors-GIST.html

    GLOBENEWSWIRE
    26 Jan 2026
    Share Share
    Cogent Biosciences Files NDA for Bezuclastinib Under RTOR
    Cogent Biosciences Files NDA for Bezuclastinib Under RTOR

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221679/0/en/Cogent-Biosciences-to-Initiate-New-Drug-Application-NDA-Submission-for-Bezuclastinib-Under-Real-Time-Oncology-Review-RTOR.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Cogent Biosciences Files NDA for Bezuclastinib Under RTOR Review
    Cogent Biosciences Files NDA for Bezuclastinib Under RTOR Review

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221679/0/en/Cogent-Biosciences-to-Initiate-New-Drug-Application-NDA-Submission-for-Bezuclastinib-Under-Real-Time-Oncology-Review-RTOR.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.